News

Latest

Feb 20, 2019
National health expenditures are projected to grow an average 5.5 percent annually during 2018-2027, outpacing average projected growth in gross domestic product by 0.8 percentage point.
Feb 20, 2019
The Centers for Medicare & Medicaid Services has extended the deadline for submitting third-quarter data to the Post-Acute Care Quality Reporting Program.
Feb 20, 2019
The Kaiser Permanente School of Medicine will waive all tuition for the full four years of school for its first five classes.
Feb 19, 2019
National hospital organizations, including the AHA, today urged congressional leaders to delay the start of the Medicaid disproportionate share hospital cuts that are scheduled to begin in fiscal year 2020.
Feb 19, 2019
The AHA today urged the Centers for Medicare & Medicaid Services to consider alternative payment solutions to promote beneficiary access to chimeric antigen receptor T-cell (CAR T) therapy and other new technologies.
Feb 19, 2019
Commenting today on the Centers for Medicare & Medicaid Services’ proposed notice of benefit and payment parameters for 2020, the AHA said it remains committed to ensuring that consumers have access to comprehensive coverage through the health insurance marketplaces.
Feb 19, 2019
The AHA Friday shared recommendations for developing a unified post-acute care prospective payment system as required by the Improving Medicare Post-Acute Care Transformation Act of 2014.
Feb 19, 2019
The AHA today voiced support for the Centers for Medicare & Medicaid Services’ proposal to rescind plans to implement the Health Plan Identifier and Other Entity Identifier in electronic health care transactions under the Health Insurance Portability and Accountability Act.
Feb 19, 2019
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Feb 15, 2019
The Centers for Medicare & Medicaid Services today proposed Medicare cover chimeric antigen receptor T-cell (CAR T) therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria.